FibroGen Inc. (NASDAQ:FGEN) CEO Thomas B. Neff sold 37,798 shares of the company’s stock in a transaction that occurred on Thursday, November 17th. The stock was sold at an average price of $22.29, for a total value of $842,517.42. Following the transaction, the chief executive officer now owns 3,341,255 shares in the company, valued at approximately $74,476,573.95. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

FibroGen Inc. (NASDAQ:FGEN) opened at 23.05 on Tuesday. The company’s market capitalization is $1.46 billion. FibroGen Inc. has a 52-week low of $14.38 and a 52-week high of $31.90. The company has a 50-day moving average price of $18.89 and a 200 day moving average price of $18.43.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.21. The business earned $30.10 million during the quarter, compared to the consensus estimate of $24.30 million. FibroGen had a negative net margin of 45.93% and a negative return on equity of 40.38%. Equities research analysts anticipate that FibroGen Inc. will post ($0.99) earnings per share for the current year.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

A number of hedge funds have recently made changes to their positions in FGEN. Vanguard Group Inc. increased its stake in shares of FibroGen by 8.8% in the second quarter. Vanguard Group Inc. now owns 4,220,201 shares of the biopharmaceutical company’s stock valued at $69,254,000 after buying an additional 339,735 shares during the last quarter. BlackRock Fund Advisors increased its stake in FibroGen by 5.7% in the third quarter. BlackRock Fund Advisors now owns 2,170,992 shares of the biopharmaceutical company’s stock valued at $44,940,000 after buying an additional 117,858 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in FibroGen by 12.6% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,449,431 shares of the biopharmaceutical company’s stock valued at $30,003,000 after buying an additional 162,548 shares in the last quarter. State Street Corp increased its stake in FibroGen by 15.1% in the first quarter. State Street Corp now owns 1,330,809 shares of the biopharmaceutical company’s stock valued at $28,335,000 after buying an additional 174,369 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in FibroGen by 0.3% in the second quarter. JPMorgan Chase & Co. now owns 1,282,804 shares of the biopharmaceutical company’s stock valued at $21,051,000 after buying an additional 3,482 shares in the last quarter. 50.07% of the stock is owned by institutional investors and hedge funds.

Several research firms recently weighed in on FGEN. Credit Suisse Group AG restated a “buy” rating and issued a $37.00 price target on shares of FibroGen in a research note on Tuesday, August 9th. Leerink Swann restated a “buy” rating and issued a $52.00 price target on shares of FibroGen in a research note on Wednesday, November 9th. Finally, Zacks Investment Research upgraded FibroGen from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Friday, November 11th.

FibroGen Company Profile

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

Receive News & Stock Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related stocks with our FREE daily email newsletter.